What is Living Cell Technologies Limited?
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 20.56M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.